PRVL Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice.
Quick AnswerPRVL — AI-powered stock analysis.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
PRVL (PRVL) Healthcare & Pipeline Overview
Who Are PRVL's Competitors?
PRVL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $37.42 | +0.05% | $166B | 91 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $503.50 | -0.64% | $129B | 97 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $731.53 | -0.45% | $75.7B | 94 5-pillar |
| ARGX argenx SE | $920.76 | -1.63% | $58.7B | 97 5-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $224.77 | -2.77% | $30.9B | 91 5-pillar |
| RPRX Royalty Pharma plc | $57.59 | -0.07% | $25.6B | 74 5-pillar |
| UTHR United Therapeutics Corporation | $563.18 | -1.44% | $24.3B | 97 5-pillar |
| INCY Incyte Corporation | $115.92 | -1.04% | $24.0B | 98 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for PRVL?
Negative return on equity (-38.2%) — the business is not currently generating profit on shareholder capital.
Key Financial Metrics
Return on equity for PRVL stands at -38.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.8%, showing how much profit it generates from its asset base. A current ratio of 14.74 indicates the company holds enough short-term assets to cover its near-term obligations.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
PRVL Latest News
-
Stocks That Hit 52-Week Highs On Wednesday
· Jan 22, 2020
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
PRVL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PRVL.
Price Targets
Wall Street price target analysis for PRVL.
PRVL MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PRVL; grades run from A+ (80-100) to F (below 30).
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.